Overview
- Insilico will use its Pharma.AI platform to design and optimize small‑molecule inhibitors targeting cardiometabolic disease.
- Qilu Pharmaceutical, including its Shanghai research center, will lead subsequent clinical development and commercialization.
- The deal includes development and commercial milestone payments totaling nearly $120 million plus single‑digit royalties on net sales.
- The collaboration builds on Qilu’s 2021 adoption of Insilico’s PandaOmics tool, moving from software use to deeper co‑development.
- Insilico cites an expanding AI‑derived pipeline with eight cardiometabolic candidates and positive Phase IIa data for rentosertib, while Qilu contributes large‑scale manufacturing capacity and top‑three industry standing in China.